Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1995-06-06
1999-09-14
Eisenschenk, Frank C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4242041, 4241881, 530324, 530326, 530327, A61K 3921, A61K 3912, A61K 3800, C07K 500
Patent
active
059519860
ABSTRACT:
Novel synthetic peptides are provided which are candidate vaccines against HIV-1 and which are useful in diagnostic application. The peptides comprise an amino acid sequence of a T-cell epitope of the gag protein of HIV-1, specifically p24E linked directly to an amino acid sequence of a B-cell epitope of the V3 loop protein of an HIV-1 isolate and containing the sequence GPGR, and/or the gp41 containing the sequence ELKDWA. Multimeric forms of the tandem synthetic peptides are provided.
REFERENCES:
patent: 5019387 (1991-05-01), Haynes et al.
patent: 5229490 (1993-07-01), Tam
Sia, et al, 1991, "Structure and immunogenicity of . . . " Sixieme Colloque Des Cent Gardes, pp. 105-110.
Sia, et al, 1992, "Construction of Synthetic HIV Vaccine Candidates" Abstract WeD1039 8.sup.th Int'l. Conf. on AIDS.
Tam, 1988, "Synthetic peptide vaccine design: Synthesis . . . ".
Wain-Hobson, et al, 1991, LAV Revisited: Origins of the early . . . " Science 252:961-965.
Sia et al, "Construction of Immunogenic Synthetic HIV Vaccine Candidates"; Proceedings of the International Conference on AIDS, Rome, II, 1992, see Abstract M.A. 68.
Sia et al, "Construction of Synthetic HIV Vaccine Candidates"; Final Program and Oral Abstracts, vol. 8, No. 1, Abstract No. WeD1039; VIII International Conference on AIDS/III STD World Congress, Amsterdam, the Netherlands, 19-24 Jul. 1992.
Luo et al, "Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies" Proc. Natl. Acad. Sci. USA, vol. 89, pp. 10527-10531 -Nov. 1992.
Tam, J.P. "Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system"; Proc. Natl. Acad. Sci. USA, vol. 85, pp. 5409-5414, Aug. 1988.
Nick et al. "Identification of HIV-1 env and gag Immunogenic Epitopes Using Sequence-Homologous Synthetic Peptides" AIDS-Forschung 6 (9): 467-473 (1991).
Shoeman et al. "Comparison of Recombinant Human Immunodeficiency Virus gag Precursor and gag/env Fusion Proteins and a Synthetic env Peptide as Diagnostic Reagents" Anal. Bioch. 161, 370-379 (1987).
Kenealy et al: "Analysis of human Serum Antibodies to Human Immunodeficiency Virus (HIV) Using Recombinant ENV and GAG antigens" AIDS Res. and Human Retrov., vol. 3, No. 1:95-105 (1987).
Cohen: Jitters Jeopardize AIDS Vaccine Trials, Science, vol. 262, pp. 980-981 (Nov. 1993).
Norley et al: "Vaccination against HIV", Immunol., vol. 184, pp. 193-207 (1992).
Palker et al: "Polyvalent Human Immunodeficiency Virus Synthetic Immunogen comprised of Envelope gp120 T Helper Cell Sites and B Cell Neutralization Epitopes" J. of Immunology, vol. 142, No. 10: 3612-3619 (1989).
Spalding, B. J. Biotechnology 10: 24-29, 1992.
Papsidero, L. P., Sheu, M. and Ruscetti, F. W. J. Virol. 63: 267-272, 1988.
Sarin, P. S., Sun, D. K., Thornton, A. H. Naylor, P. H. and Goldstein, A. L. Science 232: 1135-1137, 1986.
Palker, T.J. et al., J. of Immunol. 142: 3612-3619, 1989.
Gorny, M. K., Xu, J-Y., Gianakakos, V., Karkowska, S., Williams, C., Sheppard, H. W., Hanson, C. V. and Zolla-Pasner, S. Proc. Natl. Acad. Sci., USA, 88: 3238-3242, 1991.
Buchacher, A. et al, AIDS Research and Human Retroviruses, 10: 359-369, 1994.
Skinner, M. A., Langlois, A. J., Mcdanal, C. B., McDougal, J. S., Bolognesi, D. and Matthews, T. J. J. Virol. 62: 4195-4200, 1988.
Tam, J. P. Proc. Natl. Acad. Sci., USA. 85: 5409-5413, 1988.
Sondergard-Andersen, J. et al. Journal of Immunological Methods 131: 99-104, 1990.
O'Hagan (1992), Clin. Pharmokinet 22:1.
Ulmer et al (1993), Curr. Opinion Invest. Drugs 2(9):983-989.
Nick et al. "Identification of HIV-1 env and gag Immunogenic Epitopes Using Sequence-Homologous Synthetic Peptides" AIDS-Forschung 6 (9):467-473 (1991).
Shoeman et al. "Comparison of Recombinant Human Immunodeficiency Virus gag Precursor and gag/env Fusion Proteins and a Synthetic env Peptide as Diagnostic Reagents" Anal. Bioch. 161, 370-379 (1987).
Kenealy et al: "Analysis of Human Serum Antibodies to Human Immunodeficiency Virus (HIV) Using Recombinant ENV and GAG antigens" Aids Res. and Human Retrov., vol. 3, No. 1: 95-105 (1987).
Cohen: Jitters Jeopardize AIDS Vaccine Trials, Science, vol. 262, pp. 980-981 (Nov. 1993).
Norley et al: "Vaccination against HIV", Immunobiol, vol. 184, pp. 193-207 (1992).
Palker et al: "Polyvalent Human Immunodeficiency Virus Synthetic Immunogen comprised of Envelope gp120 T Helper Cell Sites and B Cell Neutralization Epitopes" J. of Immunology, vol. 142, No. 10: 3612-3619 (1989).
Chong Pele
Klein Michel H.
Sia Charles D. Y.
Connaught Laboratories Limited
Eisenschenk Frank C.
Nelson Brett
LandOfFree
Tandem synthetic HIV-1 peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tandem synthetic HIV-1 peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tandem synthetic HIV-1 peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1507991